Jiang Zhong Pharmaceutical Co.,Ltd provided earning guidance for the quarter ended March 31, 2022. for the quarter, the company is expected to have a total operating income of approximately RMB 890 million, representing a year-on-year increase of approximately 30% and the net profit attributable to shareholders of the listed company is expected to be approximately RMB180 million, representing a year-on-year increase of approximately 11%.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
26.25 CNY | -0.46% | -3.56% | +25.72% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.72% | 2.26B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+13.90% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- 600750 Stock
- News Jiang Zhong Pharmaceutical Co.,Ltd
- Jiang Zhong Pharmaceutical Co.,Ltd Provides Earning Guidance for the Quarter Ended March 31, 2022